LLY-283 inhibits proliferation and metastasis of head and neck squamous cell carcinoma by targeting PRMT5

doi:10.19439/j.sjos.2022.02.006

Abstract

Abstract: PURPOSE: To explore the effect of LLY-283 on the biological behavior of Head and neck squamous cell carcinoma(HNSCC) proliferation and metastasis through protein arginine methyltransferase 5(PRMT5). METHODS: TCGA database was used to analyze the expression level of PRMT5 in HNSCC tissues and cell lines by RT-PCR and Western blot. Lentiviral technology was used to construct PRMT5 knockdown stable cell line, and analyze the effect of PRMT5 on the biological behavior of HNSCC. Drug killing experiment was used to observe the IC50 changes of LLY-283 in cell lines. Nude mouse xenograft experiments were further tested to observe the biological effects of LLY-283 on HNSCC through PRMT5. RESULTS: PRMT5 was highly expressed in HNSCC tissues and cell lines, which promoted the proliferation and metastasis of cell lines, and reduced the IC₅₀ value of LLY-283. LLY-283 could significantly reduce the cell proliferation and metastasis, tumor volume and Ki-67 expression in nude mice in vivo of HNSCC through PRMT5. CONCLUSIONS: LLY-283 inhibits the expression of PRMT5 and Ki-67, thereby decreases the proliferation and metastasis of HNSCC and the ability to form transplanted tumors in nude mice, exerting anti-tumor effects.

Key words: Head and neck squamous cell carcinoma, PRMT5, LLY-283, Cell proliferation

CLC Number:

R739.8

CHEN Qi, XIE Fei, JI Ying-ying, WEI Kui-jie, REN Qiang. LLY-283 inhibits proliferation and metastasis of head and neck squamous cell carcinoma by targeting PRMT5[J]. Shanghai Journal of Stomatology, 2022, 31(2): 142-147.

References

[1] Cohen EEW, Bell RB, Bifulco CB, et al.The society for immunotherapy of cancer consensus statement on immunotherapy for the treatment of squamous cell carcinoma of the head and neck (HNSCC)[J]. J Immunother Cancer, 2019, 7(1): 184-215.
[2] Franzen A, Bootz F, Dietrich D.Prognostic and predictive methylation biomarkers in HNSCC: Epigenomic diagnostics for head and neck squamous cell carcinoma (HNSCC)[J]. Hno, 2020, 68(12):911-915.
[3] Zhu K, Song JL, Tao HR, et al.Discovery of new potent protein arginine methyltransferase 5 (PRMT5) inhibitors by assembly of key pharmacophores from known inhibitors[J]. Bioorg Med Chem Lett, 2018, 28(23-24): 3693-3699.
[4] Jing P, Zhao N, Ye M, et al.Protein arginine methyltransferase 5 promotes lung cancer metastasis via the epigenetic regulation of miR-99 family/FGFR3 signaling[J]. Cancer Lett, 2018, 427:38-48.
[5] Zakrzewicz D, Didiasova M, Kruger M, et al.Protein arginine methyltransferase 5 mediates enolase-1 cell surface trafficking in human lung adenocarcinoma cells[J]. Biochim Biophys Acta Mol Basis Dis, 2018, 1864(5 Pt A): 1816-1827.
[6] Ge L, Wang H, Xu X, et al.PRMT5 promotes epithelial-mesenchymal transition via EGFR-β-catenin axis in pancreatic cancer cells[J]. J Cell Mol Med, 2020, 24(2): 1969-1979.
[7] Qin Y, Hu Q, Xu J, et al.PRMT5 enhances tumorigenicity and glycolysis in pancreatic cancer via the FBW7/cMyc axis[J]. Cell Commun Signal, 2019, 17(1): 30-44.
[8] Li YH, Tong KL, Lu JL, et al.PRMT5-TRIM21 interaction regulates the senescence of osteosarcoma cells by targeting the TXNIP/p21 axis[J]. Aging (Albany NY), 2020, 12(3): 2507-2529.
[9] Saloura V, Vougiouklakis T, Sievers C, et al.The role of protein methyltransferases as potential novel therapeutic targets in squamous cell carcinoma of the head and neck[J]. Oral Oncol, 2018, 81: 100-108.
[10] Kumar B, Yadav A, Brown NV, et al.Nuclear PRMT5, cyclin D1 and IL-6 are associated with poor outcome in oropharyngeal squamous cell carcinoma patients and is inversely associated with p16-status[J]. Oncotarget, 2017, 8(9): 14847-14859.
[11] Amano Y, Matsubara D, Yoshimoto T, et al.Expression of protein arginine methyltransferase-5 in oral squamous cell carcinoma and its significance in epithelial-to-mesenchymal transition[J]. Pathol Int, 2018, 68(6): 359-366.
[12] Wang Y, Hu W, Yuan Y.Protein arginine methyltransferase 5 (PRMT5) as an anticancer target and its inhibitor discovery[J]. J Med Chem, 2018, 61(21): 9429-9441.
[13] Lattouf H, Poulard C, Le Romancer M.PRMT5 prognostic value in cancer[J]. Oncotarget, 2019, 10(34): 3151-3153.
[14] Liu F, Xu Y, Lu X, et al.PRMT5-mediated histone arginine methylation antagonizes transcriptional repression by polycomb complex PRC2[J]. Nucleic Acids Res, 2020, 48(6): 2956-2968.
[15] Tan Z, Chen K, Wu W, et al.Overexpression of HOXC10 promotes angiogenesis in human glioma via interaction with PRMT5 and upregulation of VEGFA expression[J]. Theranostics, 2018, 8(18): 5143-5158.
[16] Huang S, Chi Y, Qin Y, et al.CAPG enhances breast cancer metastasis by competing with PRMT5 to modulate STC-1 transcription[J]. Theranostics, 2018, 8(9): 2549-2564.
[17] Liu M, Yao B, Gui T, et al.PRMT5-dependent transcriptional repression of c-Myc target genes promotes gastric cancer progression[J]. Theranostics, 2020, 10(10): 4437-4452.
[18] Chen H, Lorton B, Gupta V, et al.A TGFβ-PRMT5-MEP50 axis regulates cancer cell invasion through histone H3 and H4 arginine methylation coupled transcriptional activation and repression[J]. Oncogene, 2017, 36(3): 373-386.
[19] Chiang K, Zielinska AE, Shaaban AM, et al.PRMT5 is a critical regulator of breast cancer stem cell function via histone methylation and FOXP1 expression[J]. Cell Rep, 2017, 21(12): 3498-3513.
[20] Chiang K, Davies CC.Linking PRMT5 to breast cancer stem cells: new therapeutic opportunities?[J]. Mol Cell Oncol, 2018, 5(3): e1441628.
[21] Zhang S, Ma Y, Hu X, et al.Targeting PRMT5/Akt signalling axis prevents human lung cancer cell growth[J]. J Cell Mol Med, 2019, 23(2): 1333-1342.
[22] Gu Z, Gao S, Zhang F, et al.Protein arginine methyltransferase 5 is essential for growth of lung cancer cells[J]. Biochem J, 2012, 446(2): 235-241.
[23] Stopa N, Krebs J E, Shechter D.The PRMT5 arginine methyltransferase: many roles in development, cancer and beyond[J]. Cell Mol Life Sci, 2015, 72(11): 2041-2059.
[24] Scaglione A, Patzig J, Liang J, et al.PRMT5-mediated regulation of developmental myelination[J]. Nat Commun, 2018, 9(1): 2840-2853.
[25] Liu L, Zhao X, Zhao L, et al.Arginine methylation of SREBP1a via PRMT5 promotes de novo lipogenesis and tumor growth[J]. Cancer Res, 2016, 76(5): 1260-1272.
[26] Wang Z, Kong J, Wu Y, et al.PRMT5 determines the sensitivity to chemotherapeutics by governing stemness in breast cancer[J]. Breast Cancer Res Treat, 2018, 168(2): 531-542.
[27] Bonday ZQ, Cortez GS, Grogan MJ, et al.LLY-283, a potent and selective inhibitor of arginine methyltransferase 5, PRMT5, with antitumor activity[J]. ACS Med Chem Lett, 2018, 9(7): 612-617.
[28] 达雨, 杨震, 夏苗苗, 等. Ki-67、PI3K、Beclin1在口腔鳞癌组织中的表达及意义[J]. 上海口腔医学, 2020, 29(1): 75-79.
[29] 张陈平. 口腔颌面头颈肿瘤诊治的挑战[J]. 口腔颌面外科杂志, 2020, 30(1): 7-10.